INBIOGEN CO.,Ltd: debt-to-equity, ROE and more
KOSPI, Legal name INBIOGEN CO.,Ltd
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 1.5%
- Equity ratio
- 98.5%
- ROE
- -0.9%
- Op. margin
- -68.8%
- Rev. growth
- -10.6%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 54.2% | 64.9% | 52.9% | -75.7% | n/a |
| FY2022 separate | 35.0% | 74.1% | -109.7% | -55.5% | 8.8% |
| FY2023 separate | 1.8% | 98.2% | 7.9% | -98.6% | -45.3% |
| FY2024 separate | 1.8% | 98.2% | 10.1% | -86.5% | 12.8% |
| FY2025 separate | 1.5% | 98.5% | -0.9% | -68.8% | -10.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩10.5B | ₩11.4B | ₩6.2B | ₩7.0B | ₩6.3B |
| Operating profit | -₩7.9B | -₩6.3B | -₩6.2B | -₩6.1B | -₩4.3B |
| Pre-tax income | ₩111.1B | -₩134.2B | ₩11.9B | ₩16.1B | -₩1.4B |
| Net income | ₩94.1B | -₩117.2B | ₩11.3B | ₩16.1B | -₩1.4B |
| Total assets | ₩274.5B | ₩144.3B | ₩145.7B | ₩162.7B | ₩160.0B |
| Total liabilities | ₩96.5B | ₩37.4B | ₩2.6B | ₩2.9B | ₩2.3B |
| Total equity | ₩178.0B | ₩106.9B | ₩143.1B | ₩159.8B | ₩157.6B |
| Paid-in capital | ₩26.7B | ₩70.4B | ₩5.0B | ₩5.0B | ₩5.0B |
| Debt/equity (source value) | 54.2% | 35.0% | 1.8% | 1.8% | 1.5% |
Company outline (FSC)
- Market
- KOSPI
- Fiscal year end
- Dec
- Founded
- 2008-03-05
- Listed
- 08/04/02
- Employees
- 28
- Auditor
- 삼일회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1313110080427
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 인바이오젠Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.